MILAN - February 5, 2016 - A retrospective analysis of the iPro2 Professional CGM from Medtronic plc (NYSE:MDT), the global leader in medical technology, demonstrates that patients with type 2 diabetes experience high rates of glycemic variability, hypoglycemia and hyperglycemia regardless of whether they manage their diabetes with diet/exercise, oral medication or insulin. Using this actionable iPro2 Professional CGM information, physicians can make therapy adjustments, recommendations and educational decisions for their patients to help improve glucose control. The results of the analysis were featured in an oral presentation at the 9th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2016).

"The use of professional CGM is on the rise. This retrospective analysis adds to a growing body of literature showing the benefits of capturing otherwise unrecognized episodes of hypoglycemia and hyperglycemia as well as identifying excessive glucose variability," said Robert A. Vigersky, M.D., medical director for Medtronic Diabetes. "Our data suggests that using Medtronic's iPro2 Professional CGM provides physicians with insights to help them optimize therapy recommendations for their patients with type 2 diabetes, no matter how they are being treated."

The retrospective analysis of over 80,000 iPro2 Professional CGM procedures in the CareLink® database included anonymized data from 70,167 patients and 353,520 patient-days in a diversely treated population of people with type 2 diabetes outside of the U.S. Results include:

• Glycemic variability: The mean glucose was 7.6±2.2 mmol/L for those on diet/exercise, 8.6±2.5 mmol/L for those on oral medication and 9.4±2.6 mmol/L for those on insulin. Variability metrics were: SD = 1.7, 2.1 and 2.8 mmol/L, respectively.
• Hypoglycemia: The daily incidence rate for hypoglycemia (defined as <3.9 mmol/L) was 0.78±0.74 for diet/exercise, 0.65±0.58 for oral medication and 0.73±0.60 for insulin.
• Hyperglycemia: All treatment groups averaged at least one episode of hyperglycemia (defined as >10.0 mmol/L) per day. The incidence rate was 1.64±1.05 for diet/exercise, 1.8±1.2 for oral medication and 1.93±0.92 for insulin.

The iPro2 Professional CGM system provides physicians with valuable insights into how their patients' diet, medication and daily activities affect glucose levels throughout an entire three-day period. Much like a Holter monitor for cardiovascular care, iPro2 Professional CGM records a patient's glucose levels 24 hours a day for up to six days (a total of 1,728 glucose readings) and provides user-friendly reports to the physician. Physicians may then use these simple reports to make therapy adjustments, recommendations and educational decisions for their patients. Medtronic recently introduced enhanced analytical capability for the iPro2 Professional CGM system. This new functionality, The CareLink iPro report, named Pattern Snapshot, helps healthcare professionals quickly uncover hidden hypoglycemic and hyperglycemic events to guide and educate their patients on improved glycemic control.

A poster of Pattern Snapshot also presented at ATTD 2016 highlights the key features of the simple, one-page CGM report that facilitates interpretation.   The report alleviates some of the physician's burden of data analysis by providing guidance for changes in diabetes management which is easily shared with patients.

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:
Amanda Sheldon
Public Relations
+1-818-576-4826

Ryan Weispfenning
Investor Relations
+1-763-505-4626